



March 24, 2026

**Brian Frazee**  
President & CEO

The Honorable Kyra Hoffner  
411 Legislative Ave  
Dover, DE 19901

**ChristianaCare**  
Janice E. Nevin, MD, MPH  
President & CEO  
DHA Board Chair

**RE: DHA Supportive Comments on the Sale and Distribution of Kratom (SB 262)**

**Bayhealth**  
Terry Murphy  
President & CEO  
DHA Board Vice-Chair

Dear Senator Hoffner,

**TidalHealth Nanticoke**  
Penny Short, MSM, BSN, RN  
President  
DHA Board Secretary & Treasurer

On behalf of Delaware's hospitals, health systems, and related healthcare organization, thank you for the opportunity to provide comments in support of Senate Bill 262, which would make it unlawful to manufacture, distribute, sell, offer for sell, or possess with intent to sell kratom products. Additionally, this bill classifies possession of a personal use quantity of a kratom product as a Class B misdemeanor.

**Beebe Healthcare**  
David A. Tam, MD, MBA  
President & CEO

According to a 2022 analysis by the Center for Disease Control and Prevention (CDC), kratom was found in 846 fatal overdose cases across 30 states and the District of Columbia. Furthermore, other reports suggest over 2,000 fatal overdoses have been linked to kratom since 2021.

**Saint Francis Hospital**  
Marlow Levy, RN, MBA,  
FACHE  
President

Delaware has made significant progress in reducing overdose deaths in the last five year, and DHA supports continued efforts to sustain this downward trend, which SB 262 seeks to do.

**Nemours Children's Health**  
Laura Kowal, MPT, JD  
Interim President  
Delaware Valley Executive Vice  
President, General Council

Thank you for the opportunity to share DHA's support for SB 262. We look forward to working with you and your colleagues in the General Assembly to advance this legislation.

**Delaware Healthcare Association**  
Brian W. Frazee  
President & CEO

Sincerely,

A handwritten signature in blue ink that reads 'Christina Bryan'.

Christina Bryan  
Vice President of External Affairs